Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

ArriVent Investigative Site, St Leonards

ArriVent Investigative Site, Blacktown

Arrivent Investigative Site, Seoul

ArriVent Investigative Site, Heidelberg

ArriVent Investigative Site, Fairfax

ArriVent Investigative Site, Madrid

ArriVent Investigative Site, Madrid

Arrivent Investigative Site, Toulouse

ArriVent Investigative Site, Celebration

ArriVent Investigative Site, Valencia

ArriVent Investigative Site, Medolla

ArriVent Investigative Site, Detroit

Arrivent Investigative Site, Gwangju

ArriVent Investigative Site, Lyon

ArriVent Investigative Site, Houston

ArriVent Investigative Site, Prescott

ArriVent Investigative Site, Whittier

Arrivent Investigative Site, Villejuif

ArriVent Investigative Site, Sacramento

Allist Investigative Site, Chaoyang

Allist Investigative Site, Beijing

Allist Investigative Site, Changchun

Allist Investigative Site, Harbin

Allist Investigative Site, Xuzhou

Allist Investigative Site, Hefei

Allist Investigative Site, Jinan

Allist Investigative Site, Jinan

Allist Investigative Site, Nanchang

Allist Investigative Site, Chongqing

Allist Investigative Site, Wuhan

Allist Investigative Site, Zhengzhou

Allist Investigative Site, Zhengzhou

Arrivent Investigative Site, Edmonton

Arrivent Investigative Site, Toronto

Allist Investigative Site, Taiyuan

ArriVent Investigative Site, Chiba

Arrivent Investigative Site, Ōsaka-sayama

Arrivent Investigative Site, Chūō

Arrivent Investigative Site, Koto-Ku

Arrivent Investigative Site, Amsterdam

ArriVent Investigative Site, Barcelona

ArriVent Investigative Site, London